Evidence map›Paper›PMID 29697951›Full record

ArticleACS chemical neuroscience2018

Effects of N-Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related Behavior.

Umberto M Battisti, Ramsey Sitta, Alan Harris, Farhana Sakloth, Donna Walther, Iwona Ruchala, S Stevens Negus, Michael H Baumann, Richard A Glennon, Jose M Eltit

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Combining Neurobehavioral Analysis andACS chemical neuroscience · 2020
    Article
  5. Article
  6. Article
  7. Using CaPsychopharmacology · 2019
    Review
  8. Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142.The Journal of pharmacology and experimental therapeutics · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Umberto M BattistiDepartment of Medicinal Chemistry, School of Pharmacy, Box 980540 , Virginia Commonwealth University , Richmond , Virginia 23298 , United States.
Ramsey SittaDepartment of Physiology and Biophysics, School of Medicine , Virginia Commonwealth University , Richmond , Virginia 23298 United States.
Alan HarrisDepartment of Physiology and Biophysics, School of Medicine , Virginia Commonwealth University , Richmond , Virginia 23298 United States.
Farhana SaklothDepartment of Pharmacology and Toxicology, School of Medicine , Virginia Commonwealth University , Richmond , Virginia 23298 , United States.
Donna WaltherDesigner Drug Research Unit, Intramural Research Program , National Institute on Drug Abuse, National Institutes of Health , Baltimore , Maryland 21224 , United States.
Iwona RuchalaDepartment of Physiology and Biophysics, School of Medicine , Virginia Commonwealth University , Richmond , Virginia 23298 United States.
S Stevens NegusDepartment of Pharmacology and Toxicology, School of Medicine , Virginia Commonwealth University , Richmond , Virginia 23298 , United States.
Michael H BaumannDesigner Drug Research Unit, Intramural Research Program , National Institute on Drug Abuse, National Institutes of Health , Baltimore , Maryland 21224 , United States.
Richard A GlennonDepartment of Medicinal Chemistry, School of Pharmacy, Box 980540 , Virginia Commonwealth University , Richmond , Virginia 23298 , United States.ORCID 0000-0002-3600-9045
Jose M EltitDepartment of Physiology and Biophysics, School of Medicine , Virginia Commonwealth University , Richmond , Virginia 23298 United States.
Virginia Commonwealth University · USNational Institutes of Health · US

Funding

Preclinical medication development for stimulant use disorderZIADA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$8.9M
Synthetic cathinones: a new class of illicit drugs affecting DAT & SERTR01DA033930 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ELTIT, JOSE MIGUEL, GLENNON, RICHARD A · 2012 to 2016
$2.7M
IMPROVING HEALTH CARE UTILIZATION IN HIV+ DRUG USERSK23DA000523 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GEBO, KELLY A · 2001 to 2005
$794k
NIDA NIH HHS K23 DA000523NIDA NIH HHS R01 DA033930
6 · The paper itself

Abstract

4-Methylamphetamine (4-MA) is an emerging drug of abuse that acts as a substrate at plasma membrane transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT), thereby causing nonexocytotic release of monoamine transmitters via reverse transport. Prior studies by us showed that increasing the N-alkyl chain length of N-substituted 4-MA analogues converts 4-MA from a transportable substrate (i.e., releaser) at DAT and NET to a nontransported blocker at these sites. Here, we studied the effects of the individual optical isomers of N-methyl-, N-ethyl-, and N- n-propyl 4-MA on monoamine transporters and abuse-related behavior in rats because action/function might be related to stereochemistry. Uptake inhibition and release assays were conducted in rat brain synaptosomes whereas electrophysiological assessments of drug-transporter interactions were examined using cell-based biosensors. Intracranial-self-stimulation in rats was employed to assess abuse potential in vivo. The experimental evidence demonstrates that S(+) N-methyl 4-MA is a potent and efficacious releaser at DAT, NET, and SERT with the highest abuse potential among the test drugs, whereas R(-) N-methyl 4-MA is a less potent releaser with reduced abuse potential. The S(+)ethyl analogue has decreased efficacy as a releaser at DAT but retains full release activity at NET and SERT with a reduction in abuse-related effects; the R(-)ethyl analogue has a similar profile but is less potent. S(+) N-Propyl 4-MA is a nontransported blocker at DAT and NET but an efficacious releaser at SERT, whereas the R enantiomer is almost inactive. In conclusion, the S enantiomers of the N-alkyl 4-MA analogues are most potent. Lengthening the N-alkyl chain converts compounds from potent nonselective releasers showing abuse-related effects to more selective SERT releasers with no apparent abuse potential.

Indexed as

Amphetamine-Related DisordersAnimalsBehavior, AnimalBrainCalciumCentral Nervous System AgentsDisease Models, AnimalHEK293 CellsHumansIsomerismMaleMethamphetamineMolecular StructureRats, Sprague-DawleySymportersSynaptosomesCalciumCentral Nervous System AgentsMethamphetamineSymportersamphetaminebath saltsdopamine transporter (DAT)drug abuseICSSMephedronenorepinephrine transporter (NET)serotonin transporter (SERT)synthetic cathinones

Identifiers

PMID29697951
PMCPMC6051915
OpenAlexW2801918541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.